GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Inventories, Finished Goods

NeoImmuneTech (XKRX:950220) Inventories, Finished Goods : ₩0.0 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Inventories, Finished Goods?


NeoImmuneTech Inventories, Finished Goods Historical Data

The historical data trend for NeoImmuneTech's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Inventories, Finished Goods Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial - - - - -

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeoImmuneTech Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


NeoImmuneTech Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech Headlines

No Headlines